Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications

References

• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54e42. quiz e30
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet. 2017;389:1741–1755.
   PubMed Web of Science ®Google Scholar
• Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145:158–65 e2.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–1605.
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology. 2006;130:1588–1594.
   PubMedGoogle Scholar
• Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut. 2011;60:631–637.
   PubMed Web of Science ®Google Scholar
• Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127:412–421.
   PubMed Web of Science ®Google Scholar
• Lee JS, Shin SJ, Collins MT, et al. Mycobacterium avium subsp. paratuberculosis fibronectin attachment protein activates dendritic cells and induces a Th1 polarization. Infect Immun. 2009;77:2979–2988.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Paccagnini D, Vidali F, et al. Detection of Mycobacterium avium subsp. paratuberculosis (MAP)-specific IS900 DNA and antibodies against MAP peptides and lysate in the blood of Crohn’s disease patients. Inflamm Bowel Dis. 2011;17:1254–1255.
   PubMed Web of Science ®Google Scholar
• Lee A, Griffiths TA, Parab RS, et al. Association of Mycobacterium avium subspecies paratuberculosis with Crohn disease in pediatric patients. J Pediatr Gastroenterol Nutr. 2011;52:170–174.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Bernstein CN, Abbas Z, et al. IBD around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the world digestive health day 2010--inflammatory bowel disease task force meeting. Inflamm Bowel Dis. 2011;17:639–644.
   PubMed Web of Science ®Google Scholar
• Oken HA, Saleeb PG, Redfield RR, et al. Is Mycobacterium avium paratuberculosis the trigger in the Crohn’s disease spectrum? Open Forum Infect Dis. 2017;4:ofx104.
   PubMed Web of Science ®Google Scholar
• Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gastroenterology. 2007;132:2313–2319.
   PubMed Web of Science ®Google Scholar
• Feller M, Huwiler K, Stephan R, et al. Mycobacterium avium subspecies paratuberculosis and Crohn’s disease: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:607–613.
   PubMed Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European Evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohn’s Colitis. 2017;11:3–25.
   Google Scholar
• Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn’s disease. Am J Gastroenterol. 2000;95:725–729.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517.
   PubMed Web of Science ®Google Scholar
• Feller M, Huwiler K, Schoepfer A, et al. Long-term antibiotic treatment for Crohn’s disease: systematic review and meta-analysis of placebocontrolled trials. Clin Infect Dis. 2010;50:473–480.
   PubMed Web of Science ®Google Scholar
• Bodini G, Giannini EG, De Maria C, et al. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn’s disease. A study performed using the Lemann index. Dig Liver Dis. 2017;49:175–180.
   PubMedGoogle Scholar
• Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn’s disease: a randomized controlled trial. Am J Gastroenterol. 2013;108:1731–1742.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–767.
   PubMed Web of Science ®Google Scholar
• Thorel MF, Krichevsky M, Levy-Frebault VV. Numerical taxonomy of mycobactin-dependent mycobacteria, emended description of Mycobacterium avium, and description of Mycobacterium avium subsp. avium subsp. nov., Mycobacterium avium subsp. paratuberculosis subsp. nov., and Mycobacterium avium subsp. silvaticum subsp. nov. Int J Syst Bacteriol. 1990;40:254–260.
   PubMedGoogle Scholar
• Naser SA, Sagramsingh SR, Naser AS, et al. Mycobacterium avium subspecies paratuberculosis causes Crohn’s disease in some inflammatory bowel disease patients. World J Gastroenterol. 2014;20:7403–7415.
   PubMed Web of Science ®Google Scholar
• Salem M, Heydel C, El-Sayed A, et al. Mycobacterium avium subspecies paratuberculosis: an insidious problem for the ruminant industry. Trop Anim Health Prod. 2013;45:351–366.
   PubMed Web of Science ®Google Scholar
• Beumer A, King D, Donohue M. Detection of Mycobacterium avium subsp. paratuberculosis in drinking water and biofilms by quantitative PCR. App Environ Microbiol. 2010;76:7367–7370.
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Microbiological Criteria for Foods. Assessment of food as a source of exposure to Mycobacterium avium subspecies paratuberculosis (MAP). J Food Protect. 2010;73:1357–1397.
   PubMed Web of Science ®Google Scholar
• Wynne JW, Bull TJ, Seemann T, et al. Exploring the zoonotic potential of Mycobacterium avium subspecies paratuberculosis through comparative genomics. PLoS One. 2011;6(7):e22171.
   PubMed Web of Science ®Google Scholar
• Koets AP, Eda S, Sreevatsan S. The within host dynamics of Mycobacterium avium ssp. paratuberculosis infection in cattle: where time and place matter. Vet Res. 2015;46:61.
   PubMed Web of Science ®Google Scholar
• Sechi LA, Dow CT. Mycobacterium avium ss. paratuberculosis zoonosis - the hundred year war - beyond Crohn’s disease. Front Immunol. 2015 Mar 4;6:96.
   PubMed Web of Science ®Google Scholar
• Cossu D, Masala S, Sechi LA. A Sardinian map for multiple sclerosis. Future Microbiol. 2013 Feb; 8(2):223–232. Review.
   PubMed Web of Science ®Google Scholar
• Whitlock RH, Wells SJ, Sweeney RW, et al. ELISA and fecal culture for paratuberculosis (Johne’s disease): sensitivity and specificity of each method. Vet Microbiol. 2000;77:387–398.
   PubMed Web of Science ®Google Scholar
• Weber MF, Verhoeff J, van Schaik G, et al. Evaluation of Ziehl-Neelsen stained faecal smear and ELISA as tools for surveillance of clinical paratuberculosis in cattle in the Netherlands. Prev Vet Med. 2009;92:256–266.
   PubMed Web of Science ®Google Scholar
• Jungersen G, Mikkelsen H, Grell SN. Use of the johnin PPD interferon-gamma assay in control of bovine paratuberculosis. Vet Immunol Immunopathol. 2012;148:48–54.
   PubMed Web of Science ®Google Scholar
• Sechi LA, Scanu AM, Molicotti P, et al. Detection and isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn’s disease in Sardinia. Am J Gastroenterol. 2005;100:1529–1536.
   PubMed Web of Science ®Google Scholar
• Borody TJ, Leis S, Warren EF, et al. Treatment of severe Crohn’s disease using antimycobacterial triple therapy--approaching a cure? Dig Liver Dis. 2002;34:29–38.
   PubMedGoogle Scholar
• van der Paardt AF, Wilffert B, Akkerman OW, et al. Evaluation of macrolides for possible use against multidrug-resistant mycobacterium tuberculosis. Eur Respir J. 2015;46:444–455.
   PubMed Web of Science ®Google Scholar
• Retsema J, Fu W. Macrolides: structures and microbial targets. Int J Antimicrob Agents. 2001;18(Suppl 1):S3–S10.
   PubMed Web of Science ®Google Scholar
• Buriankova K, Doucet-Populaire F, Dorson O, et al. Molecular basis of intrinsic macrolide resistance in the mycobacterium tuberculosis complex. Antimicrob Agents Chemother. 2004;48:143–150.
   PubMed Web of Science ®Google Scholar
• Pfister P, Jenni S, Poehlsgaard J, et al. The structural basis of macrolide-ribosome binding assessed using mutagenesis of 23S rRNA positions 2058 and 2059. J Mol Biol. 2004;342:1569–1581.
   PubMed Web of Science ®Google Scholar
• Doucet-Populaire F, Truffot-Pernot C, Grosset J, et al. Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. J Antimicrob Chemother. 1995;36:129–136.
   PubMed Web of Science ®Google Scholar
• Nash KA, Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother. 1995;39:2625–2630.
   PubMed Web of Science ®Google Scholar
• Fernandes PB, Hardy DJ, McDaniel D, et al. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother. 1989;33:1531–1534.
   PubMed Web of Science ®Google Scholar
• Rastogi N, Frehel C, Ryter A, et al. Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents? Antimicrob Agents Chemother. 1981;20:666–677.
   PubMed Web of Science ®Google Scholar
• Rastogi N, Goh KS, Labrousse V. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. Antimicrob Agents Chemother. 1992;36:2843–2846.
   PubMed Web of Science ®Google Scholar
• Alcedo KP, Thanigachalam S, Naser SA. RHB-104 triple antibiotics combination in culture is bactericidal and should be effective for treatment of Crohn’s disease associated with Mycobacterium paratuberculosis. Gut Pathog. 2016;8:32.
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012;25:545–582.
   PubMed Web of Science ®Google Scholar
• Graham DY, Al-Assi MT, Robinson M. Prolonged remission in Crohn’s disease following therapy for mycobacterium paratuberculosis infection. Gastroenterology. 1995;108:A826.
   Web of Science ®Google Scholar
• Leiper K, Martin K, Ellis A, et al. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn’s disease. Aliment Pharmacol Ther. 2008;27:1233–1239.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.
   PubMed Web of Science ®Google Scholar
• Barry VC, Belton JG, Conalty ML, et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature. 1957;179:1013–1015.
   PubMed Web of Science ®Google Scholar
• Cholo MC, Steel HC, Fourie PB, et al. Clofazimine: current status and future prospects. J Antimicrob Chemother. 2012;67:290–298.
   PubMed Web of Science ®Google Scholar
• Funk RS, Krise JP. Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction. Mol Pharm. 2012;9:1384–1395.
   PubMed Web of Science ®Google Scholar
• Cariello PF, Kwak EJ, Abdel-Massih RC, et al. Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients. Transpl Infect Dis. 2015;17:111–118.
   PubMed Web of Science ®Google Scholar
• Cholo MC, Mothiba MT, Fourie B, et al. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. J Antimicrob Chemother. 2017;72:338–353.
   PubMed Web of Science ®Google Scholar
• Ferro BE, Meletiadis J, Wattenberg M, et al. Clofazimine prevents the regrowth of mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin. Antimicrob Agents Chemother. 2016;60:1097–1105.
   PubMed Web of Science ®Google Scholar
• Mothiba MT, Anderson R, Fourie B, et al. Effects of clofazimine on planktonic and biofilm growth of mycobacterium tuberculosis and mycobacterium smegmatis. J Glob Antimicrob Resist. 2015;3:13–18.
   PubMed Web of Science ®Google Scholar
• van Ingen J, Totten SE, Helstrom NK, et al. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012;56:6324–6327.
   PubMed Web of Science ®Google Scholar
• Van Rensburg CE, Joone GK, O’Sullivan JF, et al. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob Agents Chemother. 1992;36:2729–2735.
   PubMed Web of Science ®Google Scholar
• Yano T, Kassovska-Bratinova S, Teh JS, et al. Reduction of clofazimine by mycobacterial type 2 NADH: quinoneoxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem. 2011;286:10276–10287.
   PubMed Web of Science ®Google Scholar
• Reddy VM, O’Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother. 1999;43:615–623.
   PubMed Web of Science ®Google Scholar
• Feng X, Zhu W, Schurig-Briccio LA, et al. Antiinfectives targeting enzymes and the proton motive force. Proc Natl Acad Sci U S A. 2015;112:E7073–82.
   PubMed Web of Science ®Google Scholar
• Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2013;68:284–293.
   PubMed Web of Science ®Google Scholar
• Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest. 2003;124:1482–1486.
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Long A, Lennon J, et al. Controlled trial of antimycobacterial therapy in Crohn’s disease. Clofazimine versus placebo. Dig Dis Sci. 1991;36:449–453.
   PubMed Web of Science ®Google Scholar
• van Ingen J, Egelund EF, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186:559–565.
   PubMed Web of Science ®Google Scholar
• Crabol Y, Catherinot E, Veziris N, et al. Rifabutin: where do we stand in 2016? J Antimicrob Chemother. 2016;71:1759–1771.
   PubMed Web of Science ®Google Scholar
• Levin ME, Hatfull GF. Mycobacterium smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance. Mol Microbiol. 1993;8:277–285.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yew WW. Mechanisms of drug resistance in mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13:1320–1330.
   PubMed Web of Science ®Google Scholar
• Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in mycobacterium tuberculosis. Lancet. 1993;341:647–650.
   PubMed Web of Science ®Google Scholar
• Kongpetchsatit O, Phatihattakorn W, Mahakunkijcharoen Y, et al. Mutation in the rpoB gene of the rifampicin resistant M. avium complex strains from Thailand. Southeast Asian J Trop Med Public Health. 2006;37(Suppl 3):165–173.
   PubMedGoogle Scholar
• Klein JL, Brown TJ, French GL. Rifampin resistance in mycobacterium kansasii is associated with rpoB mutations. Antimicrob Agents Chemother. 2001;45:3056–3058.
   PubMed Web of Science ®Google Scholar
• van Ingen J, van der Laan T, Dekhuijzen R, et al. In vitro drug susceptibility of 2275 clinical non-tuberculous mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents. 2010;35:169–173.
   PubMed Web of Science ®Google Scholar
• Heifets LB, Iseman MD, Lindholm-Levy PJ. Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex. Drugs Exp Clin Res. 1987;13:529–538.
   PubMedGoogle Scholar
• Dhople AM, Williams SL. The activity of rifabutin against Mycobacterium leprae in armadillos. Int J Antimicrob Agents. 1997;9:169–173.
   PubMed Web of Science ®Google Scholar
• Schon T, Chryssanthou E. Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints. Int J Infect Dis. 2017;55:122–124.
   PubMed Web of Science ®Google Scholar
• Zanetti S, Molicotti P, Cannas S, et al. Ahmed N and Sechi LA. “In vitro” activities of antimycobacterial agents against Mycobacterium avium subsp. paratuberculosis linked to Crohn’s disease and paratuberculosis. Ann Clin Microbiol Antimicrob. 2006 Nov 15;5:27.
   PubMedGoogle Scholar
• Dhople AM, Ibanez MA. In-vitro activity of three new fluoroquinolones and synergy with ansamycins against Mycobacterium leprae. J Antimicrob Chemother. 1993;32:445–451.
   PubMed Web of Science ®Google Scholar
• May T, Brel F, Beuscart C, et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 curavium group. Agence Nationale de Recherche sur le Sida. Clin Infect Dis. 1997;25:621–629.
   PubMed Web of Science ®Google Scholar
• Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis. 1999;28:1080–1085.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174:928–934.
   PubMed Web of Science ®Google Scholar
• Krishnan YK, Manning EJB, Collins MT. Comparison of three methods for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11 antimicrobial drugs. J Antimicrob Chemother. 2009;4:310–316.
   Google Scholar
• Krishnan MY, Manning EJB, Collins MT. Effects of interactions of antibacterial drugs with each other and with 6-mercaptopurine on in vitro growth of Mycobacterium avium subspecies paratuberculosis. J Antimicrob Chemother. 2009;64:1018–1023.
   PubMed Web of Science ®Google Scholar
• Behr MA, Hanley J. Antimycobacterial therapy for Crohn’s disease: a reanalysis. Lancet Infect Dis. 2008;8:344.
   PubMed Web of Science ®Google Scholar
• Kuenstner JT. The Australian antibiotic trial in Crohn’s disease: alternative conclusions from the same study. Gastroenterology. 2007;133:1742–1743.
   PubMed Web of Science ®Google Scholar
• Qasem A, Safavikhasraghi M, Naser SA. A single capsule formulation of RHB-104 demonstrates higher anti-microbial growth potency for effective treatment of Crohn’s disease associated with Mycobacterium avium subspecies paratuberculosis. Gut Pathog. 2016;8:45.
   PubMed Web of Science ®Google Scholar
• https://ir.redhillbio.com/news-releases/news-release-details/redhill-biopharma-elaborates-its-announced-positive-top-line?fbclid=IwAR2k397OF4VusXkvYS5553GPfvURrmZzpqmAKoFp5IIRZbJtpkgBe9Ii1xM
   Google Scholar